ClearPoint Neuro Inc vs JetBlue Airways Corporation — how do they compare? ClearPoint Neuro Inc trades at $14.73 (market cap $454.21M), while JetBlue Airways Corporation trades at $5.84 (market cap $2.19B). The key difference: JetBlue Airways Corporation is far larger — about 4.8× ClearPoint Neuro Inc's market cap, and JetBlue Airways Corporation is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.
| CLPT | JBLU | |
|---|---|---|
Market Cap | $454.21M | $2.19B |
Sector | Health | Industrials |
52-Week High | $29.60 | $6.46 |
52-Week Low | $8.66 | $4.03 |
Enterprise Value | $488.79M | $9.56B |
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $14.56, down slightly by 0.07% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth to $42 million but missed earnings estimates with a loss of $0.38 per share, reflecting ongoing investment in clinical and preclinical services. Despite negative net income margins and cash flow challenges, analyst consensus remains unanimously bullish with 3 buy ratings.
The outlook hinges on successful execution of growth initiatives in neuro drug delivery and regulatory progress with partners, though high valuation multiples and persistent losses pose significant risks. Near-term catalysts include Q3 2026 earnings and partner developments, but investors face volatility from operational cash burn and competitive pressures.
JetBlue (JBLU) trades at $5.64, down 7.08% amid a recent analyst downgrade. The stock shows a bullish technical signal with oversold RSI conditions, but fundamentals reveal persistent losses with a -9.32% net margin and negative ROE of -44.36%. Recent Q2 2026 earnings beat expectations, yet revenue trends remain volatile, and cash flow from operations turned negative in 2025. The company is implementing strategic fare changes and targeting 2028 profitability.
The outlook is cautious; while cost initiatives and premium product expansions offer long-term potential, high debt levels, fuel cost pressures, and inconsistent earnings pose significant risks. Analyst consensus is mixed with a hold-heavy rating and a $5.18 price target slightly below the current price, reflecting skepticism about near-term recovery.
Trailing returns across standard periods
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →